Computational development of rubromycin-based lead compounds for HIV-1 reverse transcriptase inhibition

Area of Science:

• Medicinal Chemistry
• Virology
• Computational Biology

Background:

• HIV-1 reverse transcriptase (RT) is a key target for antiretroviral therapy.
• Development of drug resistance in HIV-1 RT necessitates novel therapeutic strategies.
• Rubromycin derivatives are being explored for their potential antiviral activity.

Purpose of the Study:

• To investigate the binding affinity of rubromycin-based ligands to wild-type and mutant HIV-1 reverse transcriptase.
• To identify promising drug candidates effective against drug-resistant HIV-1 RT strains.
• To elucidate the molecular interactions governing ligand selectivity for RT mutants.

Main Methods:

• Molecular docking simulations to predict binding modes and affinities.
• Molecular dynamics simulations to analyze ligand-target interactions over time.
• Molecular Mechanics with the Poisson-Boltzmann and Surface Area (MM-PBSA) calculations for binding free energy estimation.

Main Results:

• Several rubromycin-based ligands demonstrated high predicted binding affinity for HIV-1 RT mutants.
• Identified specific compounds showing promise against RT mutants resistant to existing drugs.
• Gained insights into the factors influencing selective targeting of different RT mutants.

Conclusions:

• Rubromycin-based ligands represent a promising class of compounds for combating drug-resistant HIV-1.
• Computational approaches are valuable for identifying novel antiviral agents.
• Further studies are warranted to develop these compounds into clinical therapies.